Individuals with major depression and higher rostral anterior cingulate cortex (rACC) theta activity prior to treatment had better outcomes than those with less rACC theta activity at baseline, according to a study in JAMA Psychiatry.
The 296 patients with major depressive disorder were randomized to receive sertraline hydrochloride or placebo for 8 weeks. Among 248 patients with usable electroencephalographic (EEG) recordings, higher rACC theta activity at baseline and week 1 predicted greater depressive-symptom improvement in both placebo and treatment groups, even after controlling for other clinical and demographic variables associated with treatment outcome.
Slomski A. Brain Marker Predicts Depression Outcomes. JAMA. 2018;320(4):332. doi:10.1001/jama.2018.10156
Customize your JAMA Network experience by selecting one or more topics from the list below.